Vascepa^® is a single-molecule product. It is a highly purified omega-3 fatty acid (EPA) ethyl ester.
Vascepa^® is the only drug approved by the FDA as an adjunct to maximally tolerated statin therapy for reducing persistent CV risk in targeted high risk patients. Based on cross trial comparisons, Vascepa^® demonstrated significant efficacy advantages over evolocumab (one PCSK-9 inhibitor) and ezetimibe (one cholesterol absorption inhibitor) on top of statin therapy for reducing the risk of cardiovascular events.

We launched Vascepa^® in China in 2023.

Lusutrombopag（Mulpleta^®） is an innovative thrombopoietin receptor agonist (“TPO-RA”) with the potential breakthrough in the treatment of thrombocytopenia (“TCP”).Mulpleta^® was approved for the treatment of thrombocytopenia (TCP) in adult patients with chronic liver disease (CLD) who are scheduled to undergo a surgical procedure in Japan, the U.S. and the EU.

NMPA has approved Mulpleta® (Lusutrombopag Tablets) for the adult patients with chronic liver disease accompany thrombocytopenia who are scheduled to undergo an operation procedure (including diagnostic procedure) (CLD) as an import drug on 27th June 2023. We also plan to explore the indication expansion of Mulpleta^® to CIT（chemotherapy-induced thrombocytopenia）.

EDP 125 (Edivoxetine) is an innovative selective norepinephrine reuptake inhibitor (“SNRI”) used to treat ADHD.

We have completed the Phase III clinical trial in China for EDP 125 indicated for the treatment of ADHD in children and adolescents in January 2023 and plan to submit NDA to the NMPA in the second half of 2023.